NEW YORK - A laboratory study from Pfizer Inc/BioNTech suggests that the company’s current COVID-19 vaccine may generate a significantly less robust antibody response against the South Africa variant of the coronavirus.
According to the in vitro study published in the New England Journal of Medicine (NEJM), lab results "indicated a reduction in neutralization," of the virus."This finding is consistent with recent reports of the neutralization of variant SARS-CoV-2," Pfizer wrote in a news release published Wednesday. RELATED: Severe winter storms will cause ‘widespread delays’ in COVID-19 vaccine shipments, CDC saysResearchers analyzed blood from people who had taken the Pfizer coronavirus vaccine and identified a two-thirds reduction in.